JP2024019735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024019735A5 JP2024019735A5 JP2024000336A JP2024000336A JP2024019735A5 JP 2024019735 A5 JP2024019735 A5 JP 2024019735A5 JP 2024000336 A JP2024000336 A JP 2024000336A JP 2024000336 A JP2024000336 A JP 2024000336A JP 2024019735 A5 JP2024019735 A5 JP 2024019735A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- composition
- alkyl
- pharmaceutical composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 208000014644 Brain disease Diseases 0.000 claims 8
- 208000032274 Encephalopathy Diseases 0.000 claims 8
- 230000001037 epileptic effect Effects 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000019695 Migraine disease Diseases 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 206010015037 epilepsy Diseases 0.000 claims 5
- 206010027599 migraine Diseases 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 201000007547 Dravet syndrome Diseases 0.000 claims 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010061334 Partial seizures Diseases 0.000 claims 3
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000024658 Epilepsy syndrome Diseases 0.000 claims 2
- 208000002877 Epileptic Syndromes Diseases 0.000 claims 2
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 2
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims 2
- 208000000060 Migraine with aura Diseases 0.000 claims 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 2
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims 2
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 claims 2
- 206010067039 familial hemiplegic migraine Diseases 0.000 claims 2
- 201000007186 focal epilepsy Diseases 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 claims 1
- 208000020749 Benign familial neonatal-infantile seizures Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims 1
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 1
- 208000027109 Headache disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019476 Hemiplegic migraine Diseases 0.000 claims 1
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims 1
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims 1
- 206010021750 Infantile Spasms Diseases 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000037158 Partial Epilepsies Diseases 0.000 claims 1
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims 1
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims 1
- 201000006791 West syndrome Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 claims 1
- 208000032212 benign familial infantile 3 seizures Diseases 0.000 claims 1
- 208000017888 childhood-onset epilepsy syndrome Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738508P | 2018-09-28 | 2018-09-28 | |
| US62/738,508 | 2018-09-28 | ||
| JP2021517348A JP7576539B2 (ja) | 2018-09-28 | 2019-09-27 | イオンチャネルモジュレーター |
| PCT/US2019/053467 WO2020069322A1 (en) | 2018-09-28 | 2019-09-27 | Ion channel modulators |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517348A Division JP7576539B2 (ja) | 2018-09-28 | 2019-09-27 | イオンチャネルモジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024019735A JP2024019735A (ja) | 2024-02-09 |
| JP2024019735A5 true JP2024019735A5 (enExample) | 2024-09-06 |
Family
ID=69949703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517348A Active JP7576539B2 (ja) | 2018-09-28 | 2019-09-27 | イオンチャネルモジュレーター |
| JP2024000336A Pending JP2024019735A (ja) | 2018-09-28 | 2024-01-04 | イオンチャネルモジュレーター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517348A Active JP7576539B2 (ja) | 2018-09-28 | 2019-09-27 | イオンチャネルモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12479844B2 (enExample) |
| EP (1) | EP3856193A4 (enExample) |
| JP (2) | JP7576539B2 (enExample) |
| KR (1) | KR102842377B1 (enExample) |
| CN (1) | CN113573713A (enExample) |
| AU (2) | AU2019346635A1 (enExample) |
| BR (1) | BR112021005913A2 (enExample) |
| CA (1) | CA3142470A1 (enExample) |
| EA (2) | EA202092908A1 (enExample) |
| IL (1) | IL281946A (enExample) |
| MX (1) | MX2021003634A (enExample) |
| WO (1) | WO2020069322A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| MX2020012838A (es) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Moduladores de los canales ionicos. |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
| US20250145637A1 (en) | 2021-08-10 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co. Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
| KR20250005348A (ko) | 2022-04-26 | 2025-01-09 | 프락시스 프리시젼 메디신즈, 인크. | 신경 장애의 치료 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| KR20250173086A (ko) | 2024-05-31 | 2025-12-10 | 더웨이브컨설팅 주식회사 | 이온 채널 조절 활성을 갖는 반도비탈거미 유래 펩타이드 및 이의 용도 |
| WO2026082004A1 (zh) * | 2024-10-14 | 2026-04-23 | 上海京新生物医药有限公司 | 稠合杂芳基衍生物及其制备方法与应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| CA1080712A (en) | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4112095A (en) | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) * | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2006061428A2 (en) | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| EP1904630A4 (en) | 2005-06-16 | 2009-10-21 | Bionomics Ltd | METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE |
| HRP20170103T1 (hr) | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR100858357B1 (ko) | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| MX342128B (es) | 2008-12-24 | 2016-09-14 | Bial - Portela & C A S A | Compuestos farmaceuticos. |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| ES2642586T3 (es) * | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| WO2012151136A1 (en) | 2011-05-03 | 2012-11-08 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| WO2013045519A1 (en) | 2011-09-27 | 2013-04-04 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| WO2014179492A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| NZ720651A (en) | 2013-12-19 | 2017-12-22 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| ES2912073T3 (es) | 2014-06-20 | 2022-05-24 | Mitsubishi Chem Corp | Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| AU2015279377B2 (en) | 2014-06-26 | 2019-09-12 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2018098500A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EA201991306A1 (ru) | 2017-08-30 | 2020-03-20 | Праксис Пресижн Медсинз, Инк. | Соединения и способы их применения |
| MX2020012838A (es) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Moduladores de los canales ionicos. |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| CN114980899A (zh) | 2019-11-26 | 2022-08-30 | 普拉西斯精密医药公司 | 离子通道调节剂 |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
-
2019
- 2019-05-30 EA EA202092908A patent/EA202092908A1/ru unknown
- 2019-09-27 JP JP2021517348A patent/JP7576539B2/ja active Active
- 2019-09-27 AU AU2019346635A patent/AU2019346635A1/en not_active Abandoned
- 2019-09-27 BR BR112021005913-0A patent/BR112021005913A2/pt unknown
- 2019-09-27 US US17/280,485 patent/US12479844B2/en active Active
- 2019-09-27 WO PCT/US2019/053467 patent/WO2020069322A1/en not_active Ceased
- 2019-09-27 CN CN201980078653.2A patent/CN113573713A/zh active Pending
- 2019-09-27 EA EA202190879A patent/EA202190879A1/ru unknown
- 2019-09-27 MX MX2021003634A patent/MX2021003634A/es unknown
- 2019-09-27 KR KR1020217012574A patent/KR102842377B1/ko active Active
- 2019-09-27 CA CA3142470A patent/CA3142470A1/en active Pending
- 2019-09-27 EP EP19865432.9A patent/EP3856193A4/en active Pending
-
2021
- 2021-03-31 IL IL281946A patent/IL281946A/en unknown
-
2024
- 2024-01-04 JP JP2024000336A patent/JP2024019735A/ja active Pending
-
2025
- 2025-05-29 AU AU2025204027A patent/AU2025204027A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024019735A5 (enExample) | ||
| JP2023144130A5 (enExample) | ||
| JP2022502442A5 (enExample) | ||
| JP2021525800A5 (enExample) | ||
| EP4570313A2 (en) | Cyanotriazole compounds | |
| RU2005103244A (ru) | Производные 1h-1,2,4-триазол-3-карбоксамида в качестве лигандов рецептора каннабиноидов (cb1) | |
| RU2010154172A (ru) | Соединения для лечения рака | |
| JP2019014758A5 (enExample) | ||
| RU2013158933A (ru) | Новые модуляторы иммунной системы родственные заявки | |
| US10053474B2 (en) | Anti-viral compounds | |
| JP2022530989A5 (enExample) | ||
| JP2011500815A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2002515014A (ja) | 殺菌・殺カビ性の環式アミド類 | |
| JP2018533593A5 (enExample) | ||
| JP2013538213A5 (enExample) | ||
| JP2025515501A5 (enExample) | ||
| JP2015535851A5 (enExample) | ||
| JP2006508192A5 (enExample) | ||
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| JP2023532985A5 (enExample) | ||
| WO2020105660A1 (ja) | 新規イミダゾール誘導体 | |
| DK167015B1 (da) | 1,2,4-triazol-3-carboxamidforbindelser, fremgangsmaade til fremstilling heraf samt herbicide midler indeholdende samme | |
| EP3744719B1 (en) | Thiophene derivative and use thereof | |
| CA2576191A1 (en) | T type calcium channel inhibitors |